Biotechnology

LAEKNA-B

Laekang Medicine's LAE 002 Drug Shows Positive Results in Phase III Clinical Trials for Breast Cancer

LAEKNA-B released FY2025 Q3 earnings on March 18, 2026 (BJT) with actual revenue of HKD 55.87 M and EPS of HKD -0.1353

LAEKNA-B released FY2025 9 Months earnings on March 18 BJT, actual revenue HKD 60.75 M, actual EPS HKD -0.5092

LAEKNA-B released FY2025 Q4 earnings on March 18 After-Market (BJT), actual revenue HKD 56.83 M, actual EPS HKD -0.1376

LAEKNA-B released FY2025 annual earnings on March 18 After-Market (BJT), actual revenue HKD 116.64 M (forecast HKD 0), actual EPS HKD -0.6448 (forecast HKD -0.739)

Laekna Reports 2025 Fiscal Year Financials and R&D Progress

LAEKNA-B to release FY2025 earnings on March 18 After-Market (BJT), forecast EPS HKD -0.735

Laeke Biopharma Begins Phase 1 Clinical Trials for LAE103 in Australia

Laekang Pharmaceutical Completes First Dose Administration for LAE102 Phase I Multiple Dose Expansion Study in Obesity Treatment

Cullerna Biotech Completes Phase III Clinical Trial Enrollment for LAE 002 and Enters into Exclusive License Agreement with Qilu Pharmaceutical

Cullagenix Grants License to Qilu Pharmaceutical for Breast Cancer Candidate LAE002 in China

LAEKA Pharmaceuticals Grants QiLu Pharmaceutical Exclusive License for LAE 002 Development and Commercialization in China

DBS Research downgrades Laichai Medicine target price to HKD24.16 and reiterates 'Buy' rating

Laekna, Inc. receives analyst ratings and target price

Laichai Pharmaceutical-B's LAE102 Shows Positive Preliminary Results for Obesity Treatment

Laeknav Biopharma-B Completes Placement of 36 Million Shares at HKD 16.30

Leikai Medicine Plans to Issue 25 Million Shares

LAEKNA-B released FY2025 Q1 earnings on August 13 BJT, actual revenue HKD 2.415 M, actual EPS HKD -0.1849

LAEKNA-B released FY2025 Semi-Annual Earnings on August 13 After-Market BJT, actual revenue HKD 4.882 M, actual EPS HKD -0.3739

LAEKNA-B released FY2025 Q2 earnings on August 13 After-Market (BJT), actual revenue HKD 10.89 M, actual EPS HKD -0.1915

FAMEGLOW

CH DEMETER FIN

LUEN THAI

NEW GONOW RV

HUISHENG INTL

TJCD

HAICHANG HLDG

PARADISE ENT

ZHONGSHENJIANYE

BEST FOOD HLDG

02015

01236

00326

02225

02339

02419

02427

02105

09863

00960

LI AUTO-W(02015) fell 14.15%, with a trading turnover 3.6 Billion HKD, and a year-to-date rose 0.1%. LDROBOT(01236) fell 10.37%, with a trading turnover 30.5 Million HKD, and a year-to-date rose 56.7%. CHINA STAR ENT(00326) fell 9.84%, with a trading turnover 26.0 Million HKD, and a year-to-date rose 110.7%.

Top Gainers&Losers

LI AUTO-W

LDROBOT

CHINA STAR ENT

JINHAI MED TECH

BWI INT'L

DEKON AGR

GUANZE MEDICAL

LEAPMOTOR

LONGFOR GROUP

Top 10 HK Stock Losers (5.18)

159859

159570

159102

512290

Laekna, Inc. has scheduled its annual general meeting for June 5, 2026, in Shanghai to seek shareholder approval for its 2025 audited financial statements, the re-election of directors, and to authorize share issuance up to 20% of its issued share capital. The company aims to enhance its capital flexibility for future growth. The latest analyst rating for Laekna's stock (HK:2105) is a Buy, with a price target of HK$24.16.

Tip Ranks

Tianhong CNI BIOMEDICINE ETF

China Universal CNI HK Connect Innovative Drugs Industry ETF

China Southern Hang Seng Biotech ETF(QDII)

Minsheng Royal CSI Biotechnology Theme ETF

ChinaAMC CSI Biotechnology Theme ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

E Fund CSI Biotechnology Theme ETF

China Merchants CSI Biotechnology Theme ETF

First Trust NYSE Arca Biotech Index Fd

Hwabao WP CSI Pharmaceuticals ETF

Penghua SSE STAR Biology and Medicine ETF

Huaan Hang Seng Biotech ETF

Guotai CSI Bio-medicine ETF

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

Laekna Sets 2026 AGM to Approve 2025 Results and Share Issuance Mandate

Bank of America Securities analyst maintained a Buy rating on Laekna, Inc. on May 6 and set a price target of HK$23.50. The company’s shares closed last Wednesday at HK$13.31.Claim 55% Off TipRanksUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks Currently, the analyst consensus on Laekna, Inc. is a Strong Buy with an average price target of HK$28.62.

Bank of America

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

Bank of America Securities Reaffirms Their Buy Rating on Laekna, Inc. (2105)

In a report released yesterday, from CICC maintained a Buy rating on Laekna, Inc., with a price target of HK$27.02.Claim 30% Off TipRanksUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks Currently, the analyst consensus on Laekna, Inc. is a Strong Buy with an average price target of HK$29.91.

CICC

CICC Sticks to Their Buy Rating for Laekna, Inc. (2105)

Laekna, Inc. (HK:2105) announced positive results from its Phase III AFFIRM-205 trial for LAE002 (afuresertib) in breast cancer patients, achieving a median progression-free survival of 7.6 months. The company plans to submit a new drug application in China and is seeking global partnerships. Laekna could receive up to RMB2.045 billion in payments under its China licensing deal. Analysts rate the stock as a Buy with a price target of HK$24.16. Laekna focuses on innovative oncology therapies, particularly for patients with specific genetic alterations in breast cancer.

Laekna’s Breast Cancer Drug LAE002 Hits Phase III PFS Goal, NDA in China Planned

LAEKNA announced that its Phase III clinical trial (AFFIRM-205) achieved positive results, showing a significant improvement in progression-free survival (PFS) for LAE002 (afuresertib) combined with fulvestrant in patients with HR+/HER2- locally advanced or metastatic breast cancer. The study was a multicenter, randomized, double-blind, placebo-controlled trial that included 261 subjects, 70.5% of whom had previously received CDK4/6 inhibitor treatment

AASTOCKS

Ping An CSI Medicine and Medical Device Innovation ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

ICBCCS SSE STAR Biology and Medicine ETF

LAEKNA achieved significant improvement in PFS, reaching the primary endpoint in Phase III clinical trial for breast cancer

LAEKNA-B announced its 2025 annual performance, with revenue recorded at 107 million RMB (same below). Losses narrowed from 254 million RMB in the previous year to 229 million RMB, with a loss per share of 0.59 RMB. No dividend is declared

LAEKNA's annual loss narrowed to 229 million yuan

01428

06683

01860

00931

01757

01907

00565

02656

00863

BRIGHT SMART(01428) rose 33.96%, with a trading turnover 3.8 Billion HKD, and a year-to-date rose 14.9%. STARPLUS LEGEND(06683) rose 16.86%, with a trading turnover 1.2 Billion HKD, and a year-to-date rose 38%. MOBVISTA(01860) rose 12.99%, with a trading turnover 1.8 Billion HKD, and a year-to-date rose 10.5%.

LAEKNA-B(02105.HK)